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Objectives: To examine mutations within the penA,mtrR, porB, ponA and pilQ genes of Neisseria gonorrhoeae to
determine their contribution to cephalosporin resistance.
Methods: A total of 46 N. gonorrhoeae isolates with reduced susceptibility to cefixime or ceftriaxone
(MICs0.12 mg/L) and two susceptible isolates were selected. The full sequence of penA and partial sequences
previously reported as hot mutation sites of the other genes were analysed. Genotyping by N. gonorrhoeae
multiantigen sequence typing (NG-MAST) was also performed.
Results: A mosaic penicillin-binding protein 2 (PBP 2) was found in a single isolate that exhibited the highest
cefixime MIC (0.5 mg/L). The majority of the isolates with reduced susceptibility to cephalosporins contained
non-mosaic PBP 2 sequences, of which PBP 2 pattern XIII was most common (28/46). All isolates with
reduced susceptibility to cephalosporins also had mtrR and porB mutations. Two susceptible isolates had the
PBP 2 pattern XIV and an incomplete MtrR protein, which was a new mutation. Isolates with identical PBP 2
patterns comprised multiple NG-MAST sequence types.
Conclusions: Reduced susceptibility of N. gonorrhoeae to ceftriaxone and cefixime was associated with diverse
penA mutations, particularly PBP 2 pattern XIII containing an Ala-501!Val substitution, together with mtrR
and porB mutations. The existence of only one strain having the mosaic penA sequence indicated that ceftriax-
one and cefixime resistance in Korea is mostly not associated with a mosaic penA sequence. Highly hetero-
geneous NG-MAST sequence types excluded the clonal expansion of a particular subtype.
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Introduction
Gonorrhea remains a major sexually transmitted disease (STD) in
Korea, with 3115 reported cases in 2007 according to the STD
Sentinel Surveillance System from the National Institute of
Health, Korea (http://stat.cdc.go.kr). Effective treatment options
for Neisseria gonorrhoeae infections have been significantly
reduced over time by the emergence and spread of gonococci
resistant to penicillins, tetracyclines, macrolides and quinolones.1
Cephalosporins are now recommended as the mainstay of treat-
ment.2 The Korea Centers for Disease Control and Prevention
(KCDC) has recommended a single dose of 125 mg of intramuscular
ceftriaxone or a single dose of 400 mg of oral cefixime since 2006.
However, the emergence of N. gonorrhoeae isolates with reduced
susceptibility to cephalosporins in vitro,3–13 along with occasional
treatment failures with cefixime10,14 and ceftibuten,12 have been
reported.
Sequential alterations of the penA, mtrR, porB, ponA and pilQ
genes induce chromosomally mediated high-level resistance to
penicillin.15 A point mutation in the pilQ gene (pilQ2, previously
named penC) was recently identified, but this mutation has not
been observed in a clinical setting.15,16 Similarly, an association
has been proposed between mutations in penA, mtrR, porB and
ponA and reduced susceptibility of N. gonorrhoeae strains to
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broad-spectrum cephalosporins such as cefixime and ceftriax-
one.6,9,17 The penA mutations usually comprise insertion of a
single aspartic acid codon between Arg345 and Asp346
(R345_D346insD), along with a five or six amino acid substitution
downstream.18,19 Recently, penAmosaic alleles different from the
former non-mosaic penA mutations were identified,4,6,8,9,11,13
with mosaic alleles particularly linked to reduced susceptibility
to cefixime.4,6,8,13 However, recent studies suggest that reduced
susceptibility to ceftriaxone is not due to the presence of a
mosaic penA allele.11,20 Accordingly, the aims of this study were
to examine mutations in the penA, mtrR, porB, ponA and pilQ
genes of N. gonorrhoeae isolates with reduced susceptibility to
cefixime or ceftriaxone and to determine their contribution to
resistance.
Materials and methods
N. gonorrhoeae isolates
N. gonorrhoeae isolated from patients attending STD clinics and public
health centres during 2001–07 were studied. Of the 877 gonococci
isolated, 208 were randomly selected for antimicrobial susceptibility
testing and were stored at 2708C until further use.
A total of 48 isolates were selected for further investigation on the
basis of their ceftriaxone or cefixime MICs: 46 had reduced susceptibility
(MICs 0.12–0.5 mg/L); and 2 were susceptible (MICs0.008 mg/L).
MIC determinations
MICs of penicillin G, cefixime and ceftriaxone were determined by the
agar dilution method.21 The medium used was GC agar base (BBL;
Becton Dickinson, Cockeysville, MD, USA) supplemented with 1% haemo-
globin and 1% IsoVitaleX (BBL). Penicillin G (Sigma Chemical Co., St Louis,
MO, USA), cefixime (Dong A Pharmaceutical Co., Seoul, Korea) and cef-
triaxone (Hanmi Pharmaceutical Co., Seoul, Korea) were used. Inocula
of 104 cfu were applied using a Steers replicator (Craft Machine Inc.,
Woodline, PA, USA). Plates were incubated in a 5% CO2 incubator at
358C for 24 h after which the results were read. N. gonorrhoeae ATCC
49226 was used as a control strain.
Nucleotide sequencing of penA genes
Full-length penA nucleotide sequences from the N. gonorrhoeae strains
were determined as reported previously.13 The primers used in this study
are listed in Table 1. PCR was carried out in a total volume of 20 mL, with
1 mL of heat-extracted template DNA, 10 pmol of each primer and PreMix
(Bioneer, Cheongwon, Korea) containing 1 U of Taq DNA polymerase. A
thermal cycler (Eppendorf, Hamburg, Germany) was used with the follow-
ing conditions: 35 cycles of 948C for 1 min; 508C (penA-A1, B1), 568C
(penA-A2, B2) or 528C (penA-A3, B3) for 1 min; and 728C for 1 min. The
PCR products were extracted using a DNA extraction kit (Qiagen, Hilden,
Germany) and subjected to direct sequencing. All PCR products were
sequenced twice with forward and reverse primers using an automatic
sequencer (model 3730xl; Applied Biosystems, Weiterstadt, Germany).
Multiple-sequence alignments of nucleotide and amino acids were per-
formed using BioEdit (version 7.0.9.0). The amino acid sequence patterns
of PBP 2 were classified according to those previously described by Ito
et al.13 (I–X) and Whiley et al.11 (XI–XXIII).
Mutations in mtrR, porB, ponA and pilQ
The promoter and coding regions of mtrR, porB, ponA and pilQ were
amplified using previously described mtrR,5 porB22 and ponA5 primers
and pilQ primers newly designed from the nucleotide sequence of
N. gonorrhoeae FA 1090 (GenBank accession no. AE004969) (Table 1).
The primers were intended to amplify the partial sequences previously
reported as hot mutation sites. The parameters of the amplifications
were as follows: 35 cycles of 948C for 30 s; 508C (mtrR), 468C (porB),
568C (ponA) or 528C (pilQ) for 30 s; and 728C for 1 min. PCR products
were extracted and sequenced using the PCR primers mentioned above.
Genotyping
N. gonorrhoeae multiantigen sequence typing (NG-MAST) was conducted
by the sequencing of internal fragments of two highly polymorphic
antigen-encoding loci, por and tbpB.23 The sequence data were uploaded
onto the NG-MAST website (www.ng-mast.net) to obtain the allele
numbers and the sequence types.
Nucleotide sequence accession numbers
Nucleotide sequence data for the penA gene encoding PBP 2 with amino
acid pattern XXIV, the mtrR gene encoding the incomplete MtrR protein
and the mtrR gene encoding the MtrR protein with new amino acid sub-
stitutions (Ala-39!Thr, Leu-47!Pro) were submitted to the GenBank
nucleotide database under accession numbers FJ465093, FJ465094
and FJ465095, respectively.
Results
Alterations of PBP 2 in clinical isolates
The complete nucleotide sequences of the penA genes from 48
clinical isolates were determined. Eight amino acid sequence
patterns in PBP 2 were identified. These sequences were com-
pared with those of penicillin- and cephalosporin-susceptible
N. gonorrhoeae strain LM306 (GenBank accession no. M32091)
(Figure 1). Overall, sequence pattern XIII was most common
(28 strains), followed by pattern IV (9 strains) and pattern V
(4 strains). Sequence pattern X, a previously described mosaic
PBP 2 sequence,13 was found in only one strain. Pattern XXIV
was newly identified in this study, which was different from
pattern V by a single amino acid at position 551 (Pro-551!Ser).
Table 1. Primers used for PCR amplification and sequencing of the
penA, mtrR, porB, ponA and pilQ genes
Primer Nucleotide sequence (50 to 30) Nucleotide positions Reference
penA-A1 CGGGCAATACCTTTATGGTGGAAC 8 to 31 13
penA-B1 AACCTTCCTGACCTTTGCCGTC 655 to 676 13
penA-A2 AAAACGCCATTACCCGATGGG 597 to 617 13
penA-B2 TAATGCCGCGCACATCCAAAG 1157 to 1177 13
penA-A3 GCCGTAACCGATATGATCGA 1003 to 1022 13
penA-B3 CGTTGATACTCGGATTAAGACG 1844 to 1865 13
mtrR-F GCCAATCAACAGGCATTCTTA 2210 to 2191 5
mtrR-R GTTGGAACAACGCGTCAAAC 190 to 171 5
porB-F CCGGCCTGCTTAAATTTCTTA 241 to 222 22
porB-R TATTAGAATTTGTGGCGCAG 1030 to 1049 22
ponA-F GAGAAAATGGGGGAGGACCG 1171 to 1190 5
ponA-R GGCTGCCGCATTGCCTGAAC 1395 to 1376 5
pilQ-F CGTTACGCCGAACATCACG 1833 to 1851 this study
pilQ-R TGACCGAAACTGAACGGACTG 2358 to 2338 this study
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 10 20 30 40 50 60 70 80 90
  ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|
M32091 MLIKSEYKPRMLPKEEQVKKPMTSNGRISFVLMAMAVLFACLIARGLYLQTVTYNFLKEQGDNRIVRTQALPATRGTVSDRNGAVLALSA
IV (9) ..........................................................................................
V (4) ..........................................................................................
X (1) ..........................................................................................
XII (2) ..........................................................................................
XIII (28) ..........................................................................................
XIV (2) ..........................................................................................
XVII (1) ..........................................................................................
XXIV (1) ..........................................................................................
 100 110 120 130 140 150 160 170 180
  ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|
M32091 PTESLFAVPKDMKEMPSAAQLERLSELVDVPVDVLRNKLEQKGKSFIWIKRQLDPKVAEEVKALGLENFVFEKELKRHYPMGNLFAHVIG
IV (9) ..........................................................................................
V (4) ..........................................................................................
X (1) ..........E..........................................................A............S.......
XII (2) ..........................................................................................
XIII (28) ..........................................................................................
XIV (2) ..........................................................................................
XVII (1) ..........................................................................................
XXIV (1) ..........................................................................................
 190 200 210 220 230 240 250 260 270
  ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|
M32091 FTDIDGKGQEGLELSLEDSLYGEDGAEVVLRDRQGNIVDSLDSPRNKAPQNGKDIILSLDQRIQTLAYEELNKAVEYHQAKAGTVVVLDA
IV (9) ..........................................................................................
V (4) ..........................................................................................
X (1) ....................HAGE.........E........................................................
XII (2) ..........................................................................................
XIII (28) ..........................................................................................
XIV (2) ..........................................................................................
XVII (1) ..........................................................................................
XXIV (1) ..........................................................................................
 280 290 300 310 320 330 340 350 360
  ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|
M32091 RTGEILALANTPAYDPNRPGRADSEQRRNRAVTDMIEPGSAIKPFVIAKALDAGKTDLNERLNTQPYKIGPSPVR–DTHVYPSLDVRGIM
IV (9) ...........................................................................D..............
V (4) ...........................................................................D..............
X (1) ........V.....E..K..Q....................M...T......S..V.ATDTF..L.....SAT.Q–......T.......
XII (2) ...........................................................................D..............
XIII (28) ...........................................................................D..............
XIV (2) ...........................................................................D..............
XVII (1) ...........................................................................D..............
XXIV (1) ...........................................................................D..............
 370 380 390 400 410 420 430 440 450
  ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|
M32091 QKSSNVGTSKLSARFGAEEMYDFYHELGIGVRMHSGFPGETAGLLRNWRRWRPIEQATMSFGYGLQLSLLQLARAYTALTHDGVLLPLSF
IV (9) ..........................................................................................
V (4) ..........................................................................................
X (1) .............M.TPK.......D..V.................S....QK........................V.....E...V..
XII (2) ..........................................................................................
XIII (28) ..........................................................................................
XIV (2) ..........................................................................................
XVII (1) ..........................................................................................
XXIV (1) ..........................................................................................
 460 470 480 490 500 510 520 530 540
  ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|
M32091 EKQAVAPQGKRIFKESTAREVRNLMVSVTEPGGTGTAGAVDGFDVGAKTGTARKFVNGRYADNKHVATFIGFAPAKNPRVIVAVTIDEPT
IV (9) ......................................................L.....V.....G.......................
V (4) ......................................................L.....V.....G.......................
X (1) .......K...VI.A...KK..E.......A.......................L.....V.Y...........................
XII (2) ......................................................L.....V.....G.......................
XIII (28) ...................................................V..L.....V.....G.......................
XIV (2) ......................................................L.....V.....G.......................
XVII (1) ...................................................V..L.....V.....G.......................
XXIV (1) ......................................................L.....V.....G.......................
 550 560 570 580
  ....|....|....|....|....|....|....|....|...
M32091 AHGYYGGVVAGPPFKKIMGGSLNILGISPTKPLT–AAAVKTPS
IV (9) ..S...............................–........
V (4) ..S.......................V.......NV.......
X (1) .N...S...T..V..QV.........V.......NV.......
XII (2) ...........S......................–........
XIII (28) ...........S......................–........
XIV (2) .N................................–........
XVII (1) ..S.......................V.......NV.......
XXIV (1) ..S........S..............V.......NV.......
Figure 1. Amino acid sequences of PBP 2 from the 48 N. gonorrhoeae clinical isolates used in this study. The sequences are classified into different
amino acid patterns (patterns I–XXIV) and are aligned with a GenBank sequence (accession number M32091). Sequence patterns I–X and XI–XXIII
were previously described by Ito et al.13 and Whiley et al.,11 respectively, while pattern XXIV was identified in this study. The number of isolates
displaying each pattern is indicated in parentheses.
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Association of alteration in PBP 2 with antimicrobial
susceptibility
The distributions of the MICs of antimicrobial agents for the clini-
cal isolates associated with the PBP 2 sequence patterns are
shown in Table 2. The penicillin MIC for the isolate with the
mosaic PBP 2 structure (pattern X) was the highest for the
b-lactamase non-producing strains (Table 3). This isolate also
had the highest ceftriaxone and cefixime MICs (0.25 and
0.5 mg/L). However, four other strains with non-mosaic penA
mutations also had ceftriaxone MICs of 0.25 mg/L. The two sus-
ceptible isolates had PBP pattern XIV and displayed the lowest
MICs of the antimicrobial agents.
Mutations in mtrR, porB, ponA and pilQ
Forty-four of the 46 N. gonorrhoeae isolates with reduced suscep-
tibility to cephalosporinsharboureda single nucleotide (A) deletion
in the 13 bp inverted repeat located between the 210 and 235
sequences of the mtrR promoter (c.–57delA). The other two
isolates contained missense mutations at codons 39 and 47 in
the coding segments of mtrR that resulted in Ala-39!Thr,
Leu-47!Pro amino acid substitutions. The two susceptible iso-
lates contained a single nucleotide (G) deletion at position 81 of
the mtrR coding sequence (c.81delG). This deletion induced a
frame shift and produced a premature stop codon inmtrR, result-
ing in an incomplete MtrR protein consisting of 41 amino acids.
Non-synonymous substitutions at Gly-101 and Ala-102 of
porin encoded by porB were found in 47 clinical isolates.
Among the amino acid substitutions, Gly-101!Lys and
Ala-102!Asp were the most common (42 strains), followed by
Gly-101!Lys, Ala-102!Asn (2 strains) and Gly-101!Asn,
Ala-102!Asp (2 strains). The ponA1 allele (Leu-421!Pro in
PBP 1) was detected in 44 of the 46 clinical isolates with
reduced susceptibility and not in the two susceptible isolates.
Finally, the pilQ mutation was not found in any of the clinical iso-
lates tested.
Genotyping
A total of 38 NG-MAST sequence types were observed, of which
26 were new. The identical PBP 2 patterns were divided into
multiple NG-MAST sequence types (Table 2). The 28 strains
with PBP 2 pattern XIII, the most common PBP 2 alteration,
resolved into 19 NG-MAST sequence types.
Discussion
In the present study, the reduced susceptibility of N. gonorrhoeae
isolates to cefixime or ceftriaxone was associated with mutations
in the penA, mtrR, porB and ponA genes (Table 3). We found the
penA mosaic allele in a single clinical isolate, for the first time in
Korea. This penA mosaic sequence was identical to the sequence
(PBP 2 pattern X) identified in N. gonorrhoeae strains with reduced
susceptibility to cefixime and ceftriaxone in Japan4,8,9,13 and to
ceftriaxone in Australia.11 However, the mosaic allele was
found in only one of the 46 isolates with reduced susceptibility
to cephalosporins. This finding emphasizes the importance of
non-mosaic penA alleles in mediating reduced susceptibility
to broad-spectrum cephalosporins. Among non-mosaic penA
alleles, PBP 2 pattern XIII was observed in a large proportion
of the isolates with reduced susceptibility (28 out of 46). This
Table 2. MICs of penicillin G, cefixime and ceftriaxone for the 48 N. gonorrhoeae clinical isolates with various patterns of alterations in PBP 2
Isolate (no. of isolates
tested) No. of isolates with MIC (mg/L)
b-Lactamase PBP 2 pattern No. of NG-MAST STs Antibiotic 0.008 0.015 0.03 0.06 0.12 0.25 0.5 1 2 4 8 32 64 128
Positive all (11) PEN 3 1 7
Negative all (37) PEN 1 2 6 21 6 1
All IV (9) 8 CFX 2 3 4
CRO 7 2
V (4) 4 CFX 1 1 1 1
CRO 3 1
X (1) 1 CFX 1
CRO 1
XII (2) 2 CFX 1 1
CRO 1 1
XIII (28) 19 CFX 3 22 3
CRO 16 11 1
XIV (2) 2 CFX 2
CRO 2
XVII (1) 1 CFX 1
CRO 1
XXIV (1) 1 CFX 1
CRO 1
PEN, penicillin G; CFX, cefixime; CRO, ceftriaxone; NG, Neisseria gonorrhoeae; MAST, multiantigen sequence typing; STs, sequence types.
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Table 3. Antibiogram, mutations of penA, mtrR, porB and ponA genes and genotypes of the 48 N. gonorrhoeae clinical isolates
MIC (mg/L) Mutations in
Penicillinase Isolate no. PEN CFX CRO penA (PBP 2) mtrR porB ponA NG-MAST ST
Positive 2001-12 .128 0.12 0.06 XIII deletion of Aa G101K, A102D WT 3946b
2002-1 128 0.12 0.06 XIII A39T, L47P G101K, A102D L421P 495
2004-2 32 0.12 0.06 XIII deletion of A G101K, A102D L421P 270
2004-3 32 0.12 0.06 XIII deletion of A G101K, A102D L421P 270
2006-39 128 0.25 0.12 IV deletion of A G101K, A102D L421P 3956b
2006-43 .128 0.25 0.25 IV deletion of A G101K, A102D L421P 3956b
2007-17 128 0.12 0.12 IV deletion of A G101K, A102D L421P 3485
2007-32 64 0.06 0.12 IV deletion of A G101K, A102D L421P 3965b
2007-38 128 0.25 0.12 IV deletion of A G101K, A102D L421P 3966b
2007-53 128 0.12 0.12 IV deletion of A G101K, A102D L421P 3965b
2002-8 32 0.12 0.06 XII A39T, L47P G101K, A102D L421P 3948b
Negative 2003-9 0.25 0.008 0.008 XIV truncated MtrR WT, WT WT 1798
2006-17 0.5 0.008 0.008 XIV truncated MtrR G101K, A102D WT 3945b
2001-2 2 0.12 0.06 XIII deletion of A G101K, A102D L421P 1623
2002-3 4 0.12 0.12 XIII deletion of A G101K, A102D L421P 1623
2002-5 4 0.12 0.12 XIII deletion of A G101K, A102N L421P 3947b
2002-15 4 0.12 0.06 XIII deletion of A G101K, A102D L421P 1623
2002-21 2 0.12 0.06 XIII deletion of A G101K, A102D L421P 1623
2003-8 2 0.12 0.06 XIII deletion of A G101K, A102D L421P 3950b
2003-25 2 0.12 0.12 XIII deletion of A G101K, A102D L421P 3951b
2004-6 2 0.12 0.06 XIII deletion of A G101K, A102N L421P 3952b
2004-28 1 0.12 0.06 XIII deletion of A G101K, A102D L421P 3954b
2006-6 2 0.12 0.06 XIII deletion of A G101K, A102D L421P 972
2006-12 2 0.12 0.06 XIII deletion of A G101K, A102D L421P 3955b
2006-19 2 0.12 0.06 XIII deletion of A G101K, A102D L421P 3955b
2006-20 2 0.12 0.06 XIII deletion of A G101K, A102D L421P 3955b
2006-21 2 0.12 0.06 XIII deletion of A G101K, A102D L421P 1623
2006-23 2 0.12 0.06 XIII deletion of A G101K, A102D L421P 437
2006-34 2 0.12 0.12 XIII deletion of A G101K, A102D L421P 437
2006-35 1 0.12 0.12 XIII deletion of A G101K, A102G L421P 3976b
2006-42 0.5 0.25 0.12 XIII deletion of A G101K, A102D L421P 3957b
2007-14 2 0.25 0.25 XIII deletion of A G101K, A102D L421P 3962b
2007-19 2 0.25 0.12 XIII deletion of A G101K, A102D L421P 3963b
2007-45 1 0.12 0.12 XIII deletion of A G101K, A102D L421P 3967b
2007-50 1 0.06 0.12 XIII deletion of A G101K, A102D L421P 3967b
2007-51 1 0.06 0.12 XIII deletion of A G101K, A102D L421P 3968b
2007-61 1 0.06 0.12 XIII deletion of A G101K, A102D WT 3970b
2007-9 4 0.12 0.12 IV deletion of A G101K, A102D L421P 3961b
2007-60 2 0.25 0.25 IV deletion of A G101N, A102D L421P 3969b
2007-64 4 0.06 0.12 IV deletion of A G101K, A102D L421P 3971b
2006-44 2 0.06 0.12 V deletion of A G101K, A102D L421P 3959b
2006-45 4 0.25 0.25 V deletion of A G101K, A102D L421P 1868
2007-6 2 0.12 0.12 V deletion of A G101K, A102D L421P 3960b
2007-65 2 0.03 0.12 V deletion of A G101K, A102D L421P 3972b
2004-16 8 0.5 0.25 X deletion of A G101K, A102D L421P 3953b
2006-38 2 0.06 0.12 XII deletion of A G101K, A102D L421P 1614
2007-30 2 0.12 0.12 XVII deletion of A G101N, A102D L421P 3964b
2002-37 2 0.12 0.12 XXIV deletion of A G101K, A102D L421P 3949b
PEN, penicillin G; CFX, cefixime; CRO, ceftriaxone; WT, wild-type; NG, Neisseria gonorrhoeae; MAST, multiantigen sequence typing; ST, sequence type.
aNucleotide (A) deletion within the 13 bp inverted repeat located between the 210 and 235 sequences of the mtrR promoter.
bNew sequence types found in this study.
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PBP 2 pattern contained a substitution at position 501
(Ala-501!Val), which was considered to cause reduced suscep-
tibility to cephems in a homology modelling study.24 PBP 2
pattern XVII, which also contained the Ala-501!Val substi-
tution, was found in one isolate. In a modelling study, the
Ala-501!Val substitution and mosaic structure induced a con-
formational alteration of the b-lactam-binding pocket in PBP 2
making a major contribution to the reduced susceptibility to
cephems.24 In other transformation experiments,8 the
Ala-501!Val substitution led to a 2- to 4-fold increase in the
MICs of cefixime and other cephems. Whiley et al.11 suggested
that the Ala-501!Val substitution is more significant as a contri-
bution to ceftriaxone susceptibility than a mosaic sequence. Our
data showed the possibility that the Ala-501!Val substitution
contributed to the reduced susceptibility to broad-spectrum
cephalosporins although the penA mosaic allele has received
attention with regard to reduced susceptibility to cephalo-
sporins.4,8,12,13,17 In contrast, two isolates that were fully suscep-
tible to cephalosporins contained PBP 2 pattern XIV, consistent
with the previous study.11 This suggests that pattern XIV is not
related to reduced susceptibility to cephalosporins.
The isolates with reduced susceptibility to cephalosporins were
not restricted to any particular genotype. The isolates with identi-
cal PBP 2 patterns further resolved into multiple NG-MAST
sequence types. These results showed the heterogeneity of
N. gonorrhoeae strains with reduced susceptibility to cephalo-
sporins, as has been observed in a recent study.11 Both the pre-
vious study11 and our present study included gonococci isolated
at different times and in diverse geographical locations and com-
prised multiple subtypes.25 The heterogeneity of NG-MAST
sequence types suggests that the common occurrence of
mutations in the penA gene rather than clonal spread of a single
strain contributes to the reduced susceptibility to cephalosporins.
TheNG-MASTsequence type835,whichwas reported in the strains
with reduced susceptibility to cephalosporins from the nearby
countries of Hong Kong12 and Taiwan,26 was not found in Korea.
The isolatewith amosaic penA allele showed the highest cefix-
ime MIC (0.5 mg/L), but other isolates with non-mosaic penA
alleles also had increased cefixime MICs. The ceftriaxone MIC for
the isolate with the mosaic allele (0.25 mg/L) overlapped with
MICs for the isolates with non-mosaic penA alleles. These results
suggest that non-mosaic penAmutations are also able to increase
cephalosporins MICs to a level similar to that mediated by the
mosaic allele. Recently, a clinical isolate with a different mosaic
PBP 2, pattern XXIII, was reported to be fully susceptible to
ceftriaxone.11,20 This indicates that the mosaic PBP 2 is not suffi-
cient for reduced susceptibility to ceftriaxone. Transformation
experiments17 have shown that a significant level of cefixime
resistance was conferred by the mosaic penA allele, with only a
small contribution frommtrRand porB, whereas ceftriaxone resist-
ance was equally dependent upon both. It is possible that besides
penA,mtrR, porB and ponA, additional genetic mutations in an as
yet unidentified loci also contribute to increased resistance of
N. gonorrhoeae to cephalosporins.17
All isolates with reduced susceptibility to cephalosporins had
mtrR, porB and ponA mutations except two, which did not
have the ponA mutation (Table 3). We set the cefixime or
ceftriaxone MIC cut-offs for selecting strains for this study at
0.12 mg/L. This cut-off was chosen based on the study by Ito
et al.13 which reported mosaic penA (type X) in strains for
which the cefixime MIC was 0.12 mg/L. This high MIC cut-off
would make it very difficult to find different combinations of
several gene mutations that can be observed in N. gonorrhoeae
strains with lower MICs and to deduce the effect of each gene
mutation. However, we expect that the ponA mutation (ponA1
allele) is not important for cephalosporin resistance because
cephalosporin susceptibility was not different between isolates
with ponA mutation and isolates without the mutation if other
gene mutations were the same, supporting a recent transform-
ation study.17
Several new mutations of the mtrR gene were found in this
study. The two susceptible isolates had an incomplete MtrR
protein due to a single nucleotide (G) deletion at position 81. In
contrast, the isolates with reduced susceptibility had a deletion
in the promoter region (44 isolates) or newly found amino acid
substitutions (Ala-39!Thr, Leu-47!Pro) within MtrR (2 isolates).
Hagman and Shafer27 reported that the loss of MtrR resulted in
enhanced expression ofmtrC, but not to the same extent as that
caused by the single bp deletion in the mtrR promoter region.
The mtrR promoter overlaps the 235 sequence of mtrC, so
mutation in the promoter region can enhance binding of either
RNA polymerase or an activator to the mtrC promoter due to
decreased competition for binding on the same region of the
DNA, which induces higher resistance.27
In conclusion, reduced susceptibility of N. gonorrhoeae clinical
isolates to ceftriaxone and cefixime was associated with diverse
penA mutations, particularly PBP 2 pattern XIII containing an
Ala-501!Val substitution. The existence of only one isolate
having the mosaic penA sequence indicated that ceftriaxone
and cefixime resistance in Korea is mostly not associated with
a mosaic penA sequence. The mutations in mtrR and porB
observed in all strains with increased MICs indicate their contri-
bution to ceftriaxone and cefixime resistance. The considerable
diversity in NG-MAST sequence types excluded the clonal expan-
sion of a particular subtype.
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